Drugs / SLN12140
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06945445 | Apr 2025 → May 2026 overdue | — | Linno Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07553494 | May 2026 → Dec 2027 expected | IgA glomerulonephritis | Linno Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07387302 | Feb → Jul 2026 overdue | paroxysmal nocturnal hemoglobinuria | Linno Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLN12140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07387302 ↗ |
| Route | Intravenous | “SLN12140 for sc injection or IV infusion” NCT06945445 ↗ |
| Route | Subcutaneous | “SLN12140 for sc injection or IV infusion” NCT06945445 ↗ |